Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Interim Controller & CAO | March 01, 2022 | March 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZIMMER BIOMET HOLDINGS, INC.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2023-02-21 | Direct | 661 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 661 · Balance 661 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-02-25 | Direct | 1,026 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 1,026 · Balance 1,026 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.
F2: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 3, 2022 21:05 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-006628 · form4.xml · derivative · entry 2 Davis Derek M · CIK 0001399228 · Interim Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026 Underlying: Common Stock · 1,026 shares Expires 2024-02-25 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:05 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 661 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-006628 · form4.xml · derivative · entry 1 Davis Derek M · CIK 0001399228 · Interim Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661 Underlying: Common Stock · 661 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 22:02 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantEmployee Stock Option (right to buy) · Derivative | 7,583 | $0.00 Strike: $120.82 | $0.00 |
DisclosureSEC source: 0001062993-22-005362 · form4.xml · derivative · entry 1 Davis Derek M · CIK 0001399228 · Interim Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,583 Underlying: Common Stock · 7,583 shares Expires 2032-02-18 F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:48 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 830 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-000634 · form4.xml · derivative · entry 1 Davis Derek M · CIK 0001399228 · Interim Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830 Underlying: Common Stock · 830 shares Expires 2023-12-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.